Revenue
2020
2021
2022
2023
2024
2025
Core Scientific, Inc./tx (CORZ)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $319.0M | $510.7M | $502.4M | $640.3M | $544.5M | $60.3M |
| Gross profit | $37.9M | $121.1M | $123.5M | $8.4M | $238.9M | $9.4M |
| Research & development | — | $11.8M | $7.2M | $27.0M | $7.7M | $5.3M |
| Operating expenses | — | — | — | $253.0M | $72.2M | $21.6M |
| Operating income | −$245.6M | −$142.1M | $9.0M | −$2.11B | $131.5M | −$6.3M |
| EBITDAderived | −$176.7M | −$28.9M | $105.0M | −$1.88B | $164.9M | $3.1M |
| Net income | −$288.6M | −$1.44B | −$246.5M | −$2.15B | $47.3M | −$12.2M |
| Basic EPSper diluted share | -$0.88 | -$4.87 | -$0.65 | -$6.30 | $0.23 | -$0.14 |
| Diluted EPSper diluted share | -$0.88 | -$4.87 | -$0.65 | -$6.30 | $0.20 | -$0.14 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | DUCHENE TODD MSee remarks | SellCommon Stock | 2.4K | $29.88 | $71.7K | 2.05M |
| Jun 22, 2026Form 4 · 10b5-1 | DUCHENE TODD MSee remarks | SellCommon Stock | 7.6K | $29.11 | $221.2K | 2.05M |
| Jun 15, 2026Form 4 · 10b5-1 | DUCHENE TODD MSee remarks | SellCommon Stock | 100 | $28.79 | $2.9K | 2.06M |
| Jun 15, 2026Form 4 · 10b5-1 | DUCHENE TODD MSee remarks | SellCommon Stock | 9.9K | $28.19 | $279.1K | 2.06M |
| Jun 8, 2026Form 4 · 10b5-1 | DUCHENE TODD MSee remarks | SellCommon Stock | 4.5K | $27.11 | $122.0K | 2.07M |